To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Some people shed the kilos on semaglutide but regain all the lost weight when they get off the drug. Researchers are working ...

It's possible that Alzheimer's disease could be added to the lengthening list of ... injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able ...

Add articles to your saved list and come back to them any ... medication – this time Mounjaro, another drug that mimics the action of GLP-1. “I think, for some people, it is a lifetime medication.

Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...